138 related articles for article (PubMed ID: 35354188)
1. Oleh Hornykiewicz (1926-2020): Sixty Years since the Pioneering L-DOPA Application - One Year since the Death of the Pioneer.
Ibrahimagić OĆ; Tadić A; Kunić S; Smajlović D; Dostović Z; Iljazović A
Psychiatr Danub; 2021; 33(Suppl 4):1204-1209. PubMed ID: 35354188
[TBL] [Abstract][Full Text] [Related]
2. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
3. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
Fahn S
Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
[TBL] [Abstract][Full Text] [Related]
4. Professor Oleh Hornykiewicz on the occasion of his 75th birthday and the first L-DOPA treatment of Parkinson's disease 40 years ago.
Kobinger W
Wien Klin Wochenschr; 2001 Nov; 113(22):847-50. PubMed ID: 11762120
[No Abstract] [Full Text] [Related]
5. Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
Schlossmacher MG; Graybiel AM
Mov Disord; 2020 Nov; 35(11):1922-1932. PubMed ID: 33053225
[TBL] [Abstract][Full Text] [Related]
6. Introduction to the Special Issue on dopamine celebrating the 90th birthday of Oleh Hornykiewicz.
Sitte H; Willeit M
Eur J Neurosci; 2017 Jan; 45(1):1. PubMed ID: 28044407
[No Abstract] [Full Text] [Related]
7. Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
Rajput AH; Kish SJ
Mov Disord; 2020 Nov; 35(11):1916-1921. PubMed ID: 32985723
[No Abstract] [Full Text] [Related]
8. Current topics in brain dopamine research: a tribute to Professor Oleh Hornykiewicz.
Pifl C; Sperk G
Wien Klin Wochenschr; 2006 Oct; 118(19-20):563-5. PubMed ID: 17136327
[No Abstract] [Full Text] [Related]
9. The L-DOPA story revisited. Further surprises to be expected?
Foley P
J Neural Transm Suppl; 2000; (60):1-20. PubMed ID: 11205132
[TBL] [Abstract][Full Text] [Related]
10. Tribute: Arvid Carlsson and Oleh Hornykiewicz: Oleh Hornkiewicz.
Lloyd KG
Adv Biochem Psychopharmacol; 1977; 16():684-6. PubMed ID: 329656
[No Abstract] [Full Text] [Related]
11. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
[TBL] [Abstract][Full Text] [Related]
12. Classics in chemical neuroscience: levodopa.
Whitfield AC; Moore BT; Daniels RN
ACS Chem Neurosci; 2014 Dec; 5(12):1192-7. PubMed ID: 25270271
[TBL] [Abstract][Full Text] [Related]
13. Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.
Aquilonius SM; Nyholm D
Ups J Med Sci; 2017 Jun; 122(2):71-77. PubMed ID: 28276779
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
15. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future.
Fahn S
Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S1-S5. PubMed ID: 28784297
[TBL] [Abstract][Full Text] [Related]
16. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
17. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
Kim HJ; Jeon BS; Jenner P
Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
[TBL] [Abstract][Full Text] [Related]
18. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
19. MAO and L-dopa treatment of Parkinson's disease.
Tyce GM; Dousa MK; Muenter MD
J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
[TBL] [Abstract][Full Text] [Related]
20. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Innis RB; Marek KL; Sheff K; Zoghbi S; Castronuovo J; Feigin A; Seibyl JP
Mov Disord; 1999 May; 14(3):436-42. PubMed ID: 10348466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
